GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Tax Expense

Ascletis Pharma (HKSE:01672) Tax Expense : HK$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Tax Expense?

Ascletis Pharma's tax expense for the months ended in Dec. 2024 was HK$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00 Mil.


Ascletis Pharma Tax Expense Historical Data

The historical data trend for Ascletis Pharma's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Tax Expense Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
Get a 7-Day Free Trial Premium Member Only - - - - -

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ascletis Pharma Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascletis Pharma  (HKSE:01672) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Ascletis Pharma Tax Expense Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.
Executives
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines